Fennec Pharmaceuticals ( (FENC) ) has released its Q4 earnings. Here is a breakdown of the information Fennec Pharmaceuticals presented to its investors.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing PEDMARK, a treatment aimed at reducing the risk of ototoxicity in pediatric patients undergoing cisplatin chemotherapy. The company operates primarily within the pharmaceutical industry, with a unique focus on addressing the side effects of cancer treatments in children.
In its latest earnings report, Fennec Pharmaceuticals announced a significant increase in net product sales for its flagship product, PEDMARK, reaching $29.6 million for the full year 2024, a 40% increase compared to the previous year. The company also highlighted the commercial availability of PEDMARQSI in the United Kingdom and Germany, marking a major step in its global expansion efforts.
Key financial metrics from the report include a fourth-quarter EBITDA loss of $0.6 million and a strong cash position of $26.6 million. The company also made strategic financial moves, such as the early repayment of $13 million of its convertible debt, which is expected to save approximately $1.5 million in future interest payments. Additionally, Fennec is seeing momentum in the adolescent and young adult segment, with strategic investments driving awareness and adoption of PEDMARK.
Fennec Pharmaceuticals is also advancing its international presence, with clinical trials underway in Japan and distribution partnerships in Turkey and the Gulf Cooperation Council countries. These efforts are part of the company’s strategy to expand access to PEDMARK globally and enhance its market penetration.
Looking ahead, Fennec Pharmaceuticals is optimistic about its growth prospects, with management confident that the foundational strategies and recent commercial launches will drive significant shareholder value in 2025 and beyond.